Table 1

Randomized clinical trials evaluating antiangiogenesis agents

E4599Stage IV non-squamous, non-small cell lung, first line therapyBevacizumabII–III640Carboplatin/paclitaxel +/−a bevacizumab 15 mg/kg every 3 weeks
E2100Stage IV breast cancer, first line therapyBevacizumabII–III685Weekly paclitaxel +/− bevacizumab 10 mg/kg every 2 weeks
E3200Stage IV colorectal cancer, second line therapyBevacizumabII–III835bOxaliplatin/5-FU/leucovorin vs. oxaliplatin/5-FU/leucovorin + bevacizumab 10 mg/kg every 2 weeks; bevacizumab 10 mg/mg every 2 weeks
E3598Stage IIIA–B non-small cell lung cancer, first line therapyThalidomideIII588Sequential carboplatin/paclitaxel ⇒ Irradiation +/− thalidomide ≥ 200 mg p.o. daily
E2898Stage IV renal cell carcinomaThalidomideIII353bIFN-α 1 mμ BID s.c. +/− thalidomide ≥ 200 mg daily
E1A00Stage III myelomaThalidomideIII207bDexamethasone +/− thalidomide 200 mg daily
E1301Stage III–IV head/neck squamous cell carcinomaIFN-αIII418Surgery ⇒ IFN + 13-cis retinoic acid vs. no therapy
E1697Stage T3–4 N0 or microscopic N1 melanomaIFN-αIII1420IFN-α 20 mμ/M2 daily 5/7 days × 4 weeks vs. no therapy
E2196Stage IV breast cancer, after first line therapyMarimastatIII190cMarimastat 10 mg BID vs. placebo
  • a +/−, with and without; 5-FU, 5-fluorouracil; BID, twice a day.

  • b Completed accrual goal, data maturing.

  • c Results reported.